Probiodrug AG concentrates on developing new small molecule drugs for treating metabolic, neurological and inflammatory diseases along with auto-immune diseases.
The technology platform is based on over 20 years of experience in the field of protease research and has been systematically expanded since the company was formed in 1997. For Probiodrug, this has resulted in its dominant position in the inhibition of the glutamine cyclase (QC), a fundamental enzyme in the pathogenesis of Alzheimers disease.
In this context, Probiodrug is working to establish a new kind of treatment scheme. At the same time, it is also pursuing other approaches in the area of inflammatory diseases. The company’s core expertise is the experience it has accumulated in researching the structure and function of enzymes that play a central role in hormone maturation.
The company has conducted (on performed) pioneering work in the field of DP4 inhibition for treating type 2 diabetes. This demonstrates the company’s lively patent activity. All DP4 programmes and patents were sold in 2004. The first medication based on Probiodrug technologies was launched in 2006.